JP2015528463A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528463A5
JP2015528463A5 JP2015529881A JP2015529881A JP2015528463A5 JP 2015528463 A5 JP2015528463 A5 JP 2015528463A5 JP 2015529881 A JP2015529881 A JP 2015529881A JP 2015529881 A JP2015529881 A JP 2015529881A JP 2015528463 A5 JP2015528463 A5 JP 2015528463A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
compound according
hydroxyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015529881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528463A (ja
JP6270848B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/056418 external-priority patent/WO2014035827A1/en
Publication of JP2015528463A publication Critical patent/JP2015528463A/ja
Publication of JP2015528463A5 publication Critical patent/JP2015528463A5/ja
Application granted granted Critical
Publication of JP6270848B2 publication Critical patent/JP6270848B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015529881A 2012-08-27 2013-08-23 ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 Expired - Fee Related JP6270848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693437P 2012-08-27 2012-08-27
US61/693,437 2012-08-27
PCT/US2013/056418 WO2014035827A1 (en) 2012-08-27 2013-08-23 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Publications (3)

Publication Number Publication Date
JP2015528463A JP2015528463A (ja) 2015-09-28
JP2015528463A5 true JP2015528463A5 (https=) 2016-10-13
JP6270848B2 JP6270848B2 (ja) 2018-01-31

Family

ID=49117974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529881A Expired - Fee Related JP6270848B2 (ja) 2012-08-27 2013-08-23 ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下

Country Status (11)

Country Link
US (2) US9024042B2 (https=)
EP (1) EP2888239B1 (https=)
JP (1) JP6270848B2 (https=)
KR (2) KR102304111B1 (https=)
CN (1) CN104684904B (https=)
AU (1) AU2013309124B2 (https=)
CA (1) CA2882743C (https=)
DK (1) DK2888239T3 (https=)
ES (1) ES2711425T3 (https=)
TR (1) TR201900863T4 (https=)
WO (1) WO2014035827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201900863T4 (tr) 2012-08-27 2019-02-21 Allergan Inc Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
TR201902864T4 (tr) * 2014-02-20 2019-03-21 Allergan Inc Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
US9981938B2 (en) 2014-05-12 2018-05-29 Allergan, Inc. Quaternary ammonium alkyl esters as stable prodrugs
WO2015179815A1 (en) * 2014-05-22 2015-11-26 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
CA2962766A1 (en) * 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6353000B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
DE10322843A1 (de) 2003-05-19 2004-12-16 Clariant Gmbh Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten
WO2006047466A2 (en) 2004-10-21 2006-05-04 Duke University Ophthamological drugs
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
JP5570807B2 (ja) * 2006-07-11 2014-08-13 アラーガン インコーポレイテッド 抗緑内障薬としてのシクロペンタン誘導体
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7737140B2 (en) 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
US8592413B2 (en) * 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
US20110136872A1 (en) 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
TR201900863T4 (tr) 2012-08-27 2019-02-21 Allergan Inc Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.

Similar Documents

Publication Publication Date Title
JP2015528463A5 (https=)
JP2017537940A5 (https=)
JP2013510123A5 (https=)
JP2014511891A5 (https=)
JP2017526726A5 (https=)
JP2019524883A5 (https=)
JP2014531434A5 (https=)
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
JP2011219498A5 (https=)
JP2014511892A5 (https=)
JP2015508092A5 (https=)
RU2018128318A (ru) Селективные ингибиторы эстрогеновых рецепторов и их применение
JP2015522650A5 (https=)
JP2015528002A5 (https=)
JP2007504235A5 (https=)
JP2016526574A5 (https=)
JP2015512413A5 (https=)
JP2011137045A5 (https=)
JP2017523152A5 (https=)
JP2019535723A5 (https=)
JP2014526533A5 (https=)
RU2011102396A (ru) Аминосоединения и их медицинское применение
JP2016529235A5 (https=)
JP2020511450A5 (https=)
JP2017522304A5 (https=)